(8 Total References)
NANOPARTICLE BIOCHEM INC.
Radiology Research Faculty
Raghuraman Kannan, PhD
Above: Officers of Nanoparticle BioChem Inc. (left to right): Raghuraman Kannan, vice president; Anandhi Upendran, director of research; Henry W. White, president and CEO; Kavita Katti, chief science officer; and Kattesh V. Katti, senior vice president.
The current NBI team includes: Kattesh V. Katti, senior vice president; Raghuraman Kannan, vice president; Henry W. White, president and CEO; Kavita K. Katti, chief science officer; and Anandhi Upendran, director of research.
Nanoparticle BioChem, Inc.
took form in 2004 as a spin-off company of the University of Missouri
with several licensed technologies based on the groundbreaking discoveries of Dr. Kattesh V. Katti, Dr. Raghuraman Kannan
and Kavita K. Katti in the fields of nanoscience and nanomedicine.
Dr. Raghuraman Kannan, MU assistant professor of radiology and vice president of NBI says: "The availability of a vast state-of-the-art research and product development infrastructure at MU provides a strong synergy for mutual advancement of NBI and the University of Missouri's entrepreneurial enterprise."
"This group is a great one with which to work, and I am delighted to assist Dr. Katti, Dr. Kannan, Dr. Anandhi Upendran and Kavita Katti in their product development and commercialization efforts," says NBI CEO White, a former chair of MU's physics and astronomy department.
"It is absolutely critical that individuals, such as Dr. Kannan
, and Dr. Katti and other faculty, are able to consult and lend their expertise to spin-off companies such as NBI
for both the generation of new technologies that benefit society and the creation of high technology jobs that benefit our economy.
Raghuraman Kannan, Assistant ...
Raghuraman Kannan, Assistant Professor, University of Missouri
Nanoparticles Show Promise in Cancer Detection and Treatment
Agents that can detect cancer at this stage with an imaging technique, such as CT, will significantly increase our ability to detect cancer during regular check-up visits,, said Raghuraman Kannan, Ph.D., a member of the research team and an assistant professor in the Department of Radiology at the University of Missouri.
,Toxicity studies of nanoparticles need to be thoroughly investigated before we proceed further in utilizing them for a clinical setting,, Dr. Kannan
One advantage that may catalyze efforts toward human testing is that the same CT scanners already in use in hospitals can be used if gold nanoparticles are part of contrast imaging.
"Nanoparticles would be ideal candidates in CT diagnosis of different diseases such as cancer, asthma, emphysema and cystic fibrosis, , said Dr. Katti. ,We hope that nanoparticles will increase the sensitivity, as well as the scope of diagnostic imaging.,
undefined(back row, from left) Evan Boote, PH.D., Robert Churchill, M.D., Amanda Tinsley, B.S., Sharanya Bhaskaran, B.S., Ravi pandrapragada, M.S. (front row, from left) Kavita Katti, B.S., Kattesh V. Katti, Ph.D., Raghuraman Kannan, Ph.D., Leah Arrigo, B.S., Chandrika Mysore, M.S.